Identifying New Therapeutics
Eshelman professor secures secures $2.2 million to develop leukemia, lymphoma treatment.
Eshelman professor secures secures $2.2 million to develop leukemia, lymphoma treatment.
UNC Eshelman School of Pharmacy Associate Professor Qisheng Zhang was recently awarded a $2,247,857 grant from the National Cancer Institute to study mutations in lymphomas and leukemias with the goal of identifying new therapeutics.
The four-year grant will support his work, “A high-throughput platform to identify selective allosteric inhibitors of the PLC-g isozymes.” Co-investigators on the study include Eshelman faculty John Sondek and Kenneth Pearce Jr.
“Our goal is to discover selective inhibitors to further understand how hyperactive PLC-g proteins drive cancer and ultimately to develop novel approaches to treat leukemias and lymphomas,” Zhang said.
Read the complete Carolina Story…Opens in new window
